Moderna
MRNA
106 hedge funds and large institutions have $2.8B invested in Moderna in 2019 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 18 closing their positions.
150% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 18
40% more capital invested
Capital invested by funds: $2.01B → $2.8B (+$795M)
34% more funds holding
Funds holding: 79 → 106 (+27)
17% more call options, than puts
Call options by funds: $6.91M | Put options by funds: $5.9M
1.44% more ownership
Funds ownership: 40.61% → 42.05% (+1.4%)
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$23.4M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$15.8M |
| 3 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$13.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.1M |
| 5 |
BlackRock
New York
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highline Capital Management
New York
|
-$10.9M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$7.67M |
| 3 |
SC
Samlyn Capital
New York
|
-$4.96M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.64M |
| 5 |
Neuberger Berman Group
New York
|
-$4.49M |
MRNA Hedge Fund Activity: Q1 2019 in Review
106 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q1 2019, worth a combined $2.8B — up 40% from $2.01B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new MRNA positions and 18 closed out — a net gain of 27 holders — while 25 added to existing stakes and 23 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $23.4M. The largest seller was Highline Capital Management, cutting an estimated $10.9M.
- 106 institutional investors held Moderna (MRNA) as of Q1 2019, up from 79 in Q4 2018.
- Funds reported $2.8B of Moderna stock for Q1 2019, up 40% quarter-over-quarter.
- 45 funds opened new Moderna positions in Q1 2019 and 18 closed out, a net change of +27 holders.
- The largest Moderna buyer in Q1 2019 was Morgan Stanley, an estimated $23.4M added.
- The largest Moderna seller in Q1 2019 was Highline Capital Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2019.